A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy Volunteer

In brief

The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Key facts

Study ID

NCT07413133

Run by

AbbVie

People needed

40

Starts

2026-02-11

Expected to finish

2026-06-19

Last updated by the study team

2026-07-20

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
• Body weight >= 35 kg.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).

You may not qualify if…

• Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis.
• Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration.
• Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration.
• Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.

Where it is running

• CenExel ACT- Anaheim Clinical Trials /ID# 280481 — Anaheim, California, United States
• Acpru /Id# 280382 — Grayslake, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.